BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:29 PM
 | 
Aug 27, 2012
 |  BC Extra  |  Clinical News

Effient misses Phase III endpoint vs. Plavix

Daiichi Sankyo Co. Ltd. (Tokyo:4568; Osaka:4568) and Eli Lilly and Co. (NYSE:LLY) said Effient prasugrel plus low-dose aspirin missed the composite primary endpoint vs. Plavix clopidogrel plus low-dose aspirin in the Phase III TRILOGY ACS trial to treat acute coronary syndrome patients...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >